Evidence map›Paper›PMID 39948366›Full record

Trial reportScientific reports2025

Testing the iMplementation Framework fOr behavioral and LIfestyLe interventions in AlZheimer's DiseasE (MOBILIZE) via the ACT randomized controlled trial.

Dereck L Salisbury, F Vankee Lin, Fang Yu

Registry-linked trialAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03313895 (Efficacy and Mechanisms of Combined Aerobic Exercise and Cognitive Training), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03313895 nacompletednot on this map

Efficacy and Mechanisms of Combined Aerobic Exercise and Cognitive Training (ACT) in MCI

TypeinterventionalSponsorArizona State UniversityRan2018 to 2024Enrolled146ConditionsMild Cognitive ImpairmentArmsAerobic & Cognitive Training (ACT), Cycling Only, Cognitive Training Only, Stretching and Mental Stimulating Activities
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Dereck L SalisburyUniversity of Minnesota School of Nursing, Minneapolis, MN, USA.
F Vankee LinDepartment of Psychiatry and Behavioral Sciences, Stanford University, Palo Alto, CA, USA. Vankee_Lin@stanford.edu.
Fang YuArizona State University Edson College of Nursing and Health Innovation, 500 N 3rd St, Mail Code 3020, Phoenix, AZ, 85004, USA. Fang.Yu.2@asu.edu.

Funding

Efficacy and Mechanisms of Combined Aerobic Exercise and Cognitive Training in MCI_The ACT Trial COVID Admin SupR01AG055469 · NIA · UNIVERSITY OF MINNESOTA · PI LIN, FENG VANKEE, YU, FANG · 2017 to 2023
$4.4M
NIA NIH HHS R01 AG055469NIA NIH HHS R01AG055469-01A1
6 · The paper itself

Abstract

Implementing multi-site behavioral intervention trials to study Alzheimer's disease (AD) has many unique challenges, leading to substantial variations in delivered intervention doses and cognitive findings. These issues can be addressed by the IMplementation Framework fOr Behavioral and LIfestyLe Interventions In AlZheimer's DiseasE (MOBILIZE), which was developed to guide the design and implementation of behavioral interventions in AD. Building on the person-centered principle, MOBILIZE includes three implementation outcomes with corresponding team processes: (1) screening (processes), (2) intervention adherence (processes), and (3) safety (processes). This study systematically evaluated MOBILIZE implementation outcomes of the 3-site aerobic exercise and cognitive training (ACT) Trial (recruitment started on 4/1/2018 and last follow-up on 7/17/2024). Outcomes included time in screening phases, intervention adherence (attendance and intervention dose adherence, and safety [adverse events]). Sample (n = 146) was 73.8 ± 5.7 years in age and 23.4 ± 2.1 on Montreal Cognitive Assessment score, with 48.0% female and 91.8% White. The median days of screening-to-enrollment averaged 98 days. Attendance was 76.7 ± 28.6%. Adherence to 100% exercise session dose and 100% cognitive session dose was 71.7 ± 30.8% and 51.5 ± 26.2%, respectively. There were 10 study-related adverse events. MOBILIZE helped the ACT Trial achieve high intervention attendance and safety and may be important for early-stage trials in AD.Trial registration The ACT Trial is registered at clinicaltrials.gov (NCT03313895). Registered 15 July 2017, https://clinicaltrials.gov/study/NCT03313895 .

Indexed as

Alzheimer DiseaseLife StyleAdultAgedExerciseFemaleHumansMaleMiddle AgedClinical trialsCognitive trainingExercise trainingMild cognitive impairment

Identifiers

PMID39948366
PMCPMC11825660

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.